Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Phase 2
1(25.0%)
4Total
Phase 1(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05643638Phase 2Recruiting

A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD

Role: lead

NCT05165628Phase 1Completed

Safety, Tolerability and Efficacy of CYP-006TK in Adults with Diabetic Foot Ulcers

Role: lead

NCT04537351Phase 1Completed

The MEseNchymal coviD-19 Trial: MSCs in Adults With Respiratory Failure Due to COVID-19 or Another Underlying Cause

Role: lead

NCT02923375Phase 1Completed

A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease

Role: lead

All 4 trials loaded